Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Mo Qatanani, Chief Scientific Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), sold 24,066 shares of common stock on July 8, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The company, currently valued at $3.6 billion, has seen its stock surge over 326% in the past year, according to InvestingPro data. The shares were sold at a weighted average price of $34.4427, for a total transaction value of $828,898. The prices for the shares sold ranged from $32.45 to $44.32.
Following the transaction, Qatanani directly owns 115,495 shares of Scholar Rock Holding Corp, which includes 115,495 restricted stock units (RSUs).
The sale was executed under a Rule 10b5-1 trading plan adopted by Qatanani on March 31, 2025.
In other recent news, Scholar Rock has reported significant developments surrounding its apitegromab therapy. The company announced positive results from its Phase 2 EMBRAZE trial, where apitegromab, combined with tirzepatide, preserved 54.9% more lean mass compared to tirzepatide alone during weight loss treatments. This finding suggests potential for higher quality weight loss, as the combination therapy resulted in a greater proportion of fat loss compared to lean mass. Meanwhile, Truist Securities reiterated its buy rating and $45.00 price target for Scholar Rock, emphasizing the potential of apitegromab for treating spinal muscular atrophy (SMA). The analyst firm noted that apitegromab could see broader usage beyond current projections if reimbursement challenges are absent. H.C. Wainwright also maintained a buy rating and set a $50.00 price target, citing the promising Phase 2 trial results. In addition, Scholar Rock appointed Rebecca McLeod as Chief Brand Officer and U.S. General Manager to lead the commercial launch of apitegromab in the United States. McLeod’s experience in launching treatments for neuromuscular diseases is expected to bolster the company’s efforts in addressing SMA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.